

Rebates and National Procurement Pricing Agreements

The Pharmacy & Medicines Optimisation Team (PMOT) of the Hertfordshire and West Essex Integrated Care Board (HWE ICB) considers offers of rebates on primary care prescribing costs in line with Appendix A.

The rebates in place across HWE ICB are listed below and are published on the website. They will only be collected in the place-based areas where the products are recommended on the place-based formulary. Where this differs between areas this is stated below.

Company	Product	PrescQIPP Approved?	Current Agreement Start Date	Current Agreement End Date
Chiesi	Clenil Modulite Beclometasone Dipropionate Inhaler (200 dose units) 50mcg/100mcg/200mcg/250mcg	No significant reservations	01.07.2024	30.06.2026
Chiesi	Fostair pMDI & Fostair Nexhaler Beclometasone dipropionate/formoterol fumarate dihydrate	No significant reservations	01.07.2024	30.06.2026
Daiichi-Sankyo	Lixiana – Edoxaban tablets (all strengths) This is a volume-based rebate which is withdrawn if our market share drops below a certain level.	PrescQIPP assessment tool is not applicable to this scheme	01-04-2025	31-03-2027
Abbott	Freestyle Libre device & Freestyle libre 2 (these rebates will be stopping when the rebate expires)	Not submitted to PrescQIPP	01.07.2024	30.6.2025
Abbott	Freestyle Libre 2 plus	Not submitted to PrescQIPP	01.07.2025	01.07.2026
Nestle	Resource thicken up clear (Herts only, not formulary in W Essex)	Not reviewed as Nestle did not submit it to PrescQIPP	01.04.2023	n/a

Appendix A: NHS Herts and West Essex Integrated Care Board Primary Care Prescribing Pricing Agreement Process

The HWE ICB pricing agreement list is reviewed regularly, ratified and the update re-published on the website if there are changes.

HWE ICB PMOT will only consider rebates on formulary medicines and prefer rebates which are approved by PrescQIPP. The PrescQIPP documentation can be found at: <https://www.prescqipp.info/our-resources/webkits/primary-care-rebates/> (need to register and login to access).

PrescQIPP is a national organisation hosted and funded by the NHS to support quality prescribing in the NHS. PrescQIPP undertake a financial and clinical review of the offer and assist commissioners in managing the legal implications of entering into the presented schemes.

The PrescQIPP board gives an Assessment; **no significant reservations or reservations identified.**

Local ICB Process:

Only formulary agents will be considered for rebates.

The PrescQIPP evaluation of rebates is considered and discussed by a Senior Pharmacist within PMOT using the consideration list below. If assessed, the rating given by PrescQIPP is considered as part of the process for agreeing a rebate. If PrescQIPP assess as “with some reservations identified” we would review issues which can be managed locally by HWE ICB.

e.g.

- legal clauses which HWE ICB senior PMOT staff understand, and feel are low risk
 - provision of price together with quantity prescribed – where local assessment differs from PrescQIPP (e.g. due to preferred local use leading to high value of savings)
 - short term 1 or 2 years provided product in current use and on formulary
- then these rebates will be carefully considered by PMOT independently.

If we accept a rebate that is not yet assessed by PrescQIPP we inform PrescQIPP staff that the rebate exists and we will review the PrescQIPP assessment when they classify it.

The ICB Chief Financial Officer will individually ‘sign-off’ all agreements on behalf of HWE ICB.

The summary of rebates collected is documented and reviewed by the appropriate medicines committee of the HWE ICB.

For a rebate to be considered by PMOT the following conditions need to be met:

1. The proposed scheme does not require a change in an existing clinical pathway (e.g. NICE/ local guidance/ best practice) or to medication use.
2. The medicine or medical device for which the pricing agreement concerns is currently agreed by the Hertfordshire and West Essex Medicines Optimisation Delivery & Implementation Group (MODIG) for prescribing in primary care
3. The proposed medicine or medical device is being recommended within its product license.
4. The proposed scheme does not include an exclusivity clause that would restrict the individual prescriber's clinical freedom.
5. The anticipated net rewards through the proposed scheme are of sufficient value to warrant engagement. This value is defined locally.
6. The collection of the saving is simple to administer.
7. The length of the proposed scheme should be at least one year for HWE ICB to realize potential savings.
8. Engaging with the proposed pricing agreement should not encourage prescribing contrary to HWE ICB prescribing policies.
9. The integrity of HWE ICB should not be compromised in any way by engaging in the proposed pricing agreement scheme.
10. The Freedom of Information (FOI) clause in the agreement must not restrict compliance of HWE ICB with its FOI obligations. Ideally 'redacted' agreements will be supplied by the manufacturer and held by HWE ICB staff to facilitate response to FOIs.

Version	4.0
Developed by	Sarah Crotty, Lead Pharmacist, HWE PMOT (With thanks to Derbyshire CCG and North Kirklees CCG)
Date ratified	Version 4.0 reviewed by May 2025 MODIG Version 3.0 approved at July 2024 HWE ICS Medicines Optimisation meeting (MODIG) Version 2.0 was approved at May 2023 MODIG and subsequent Primary Care Commissioning Committee (PCCC) Version 1.0 was a Herts Valleys CCG document